Literature DB >> 23723951

1,3-Bis[(3-chloro-pyrazin-2-yl)-oxy]benzene.

Thothadri Srinivasan1, Venkatesan Kalpana, Perumal Rajakumar, Devadasan Velmurugan.   

Abstract

The asymmetric unit of the title compound, C14H8Cl2N4O2, contains one half-mol-ecule, the complete mol-ecule being generated by the operation of a twofold rotation axis. The Cl atom deviates significantly from the plane of the pyrazine ring [0.0215 (4) Å]. The central benzene ring makes a dihedral angle of 72.82 (7)° with the plane of the pyrazine ring.

Entities:  

Year:  2013        PMID: 23723951      PMCID: PMC3648331          DOI: 10.1107/S160053681301129X

Source DB:  PubMed          Journal:  Acta Crystallogr Sect E Struct Rep Online        ISSN: 1600-5368


Related literature

For applications of the pyrazine ring system in drug development, see: Du et al. (2009 ▶); Dubinina et al. (2006 ▶); Ellsworth et al. (2007 ▶); Mukaiyama et al. (2007 ▶). For background to the fluorescence properties of compounds related to the title compound, see: Kawai et al. (2001 ▶); Abdullah (2005 ▶). For a related structure, see: Nasir et al. (2010 ▶).

Experimental

Crystal data

C14H8Cl2N4O2 M = 335.14 Monoclinic, a = 9.9618 (3) Å b = 10.2196 (4) Å c = 14.6010 (6) Å β = 106.231 (2)° V = 1427.22 (9) Å3 Z = 4 Mo Kα radiation μ = 0.47 mm−1 T = 293 K 0.30 × 0.25 × 0.20 mm

Data collection

Bruker SMART APEXII area-detector diffractometer Absorption correction: multi-scan (SADABS; Bruker, 2008 ▶) T min = 0.873, T max = 0.912 6736 measured reflections 1781 independent reflections 1552 reflections with I > 2σ(I) R int = 0.026

Refinement

R[F 2 > 2σ(F 2)] = 0.036 wR(F 2) = 0.113 S = 1.00 1781 reflections 101 parameters H-atom parameters constrained Δρmax = 0.25 e Å−3 Δρmin = −0.31 e Å−3 Data collection: APEX2 (Bruker, 2008 ▶); cell refinement: SAINT (Bruker, 2008 ▶); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008 ▶); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008 ▶); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012 ▶) and Mercury (Macrae et al., 2008 ▶); software used to prepare material for publication: SHELXL97and PLATON (Spek, 2009 ▶). Click here for additional data file. Crystal structure: contains datablock(s) global, I. DOI: 10.1107/S160053681301129X/kp2450sup1.cif Click here for additional data file. Structure factors: contains datablock(s) I. DOI: 10.1107/S160053681301129X/kp2450Isup2.hkl Click here for additional data file. Supplementary material file. DOI: 10.1107/S160053681301129X/kp2450Isup3.cml Additional supplementary materials: crystallographic information; 3D view; checkCIF report
C14H8Cl2N4O2F(000) = 680
Mr = 335.14Dx = 1.560 Mg m3
Monoclinic, C2/cMo Kα radiation, λ = 0.71073 Å
Hall symbol: -C 2ycCell parameters from 1781 reflections
a = 9.9618 (3) Åθ = 2.9–28.4°
b = 10.2196 (4) ŵ = 0.47 mm1
c = 14.6010 (6) ÅT = 293 K
β = 106.231 (2)°Block, colourless
V = 1427.22 (9) Å30.30 × 0.25 × 0.20 mm
Z = 4
Bruker SMART APEXII area-detector diffractometer1781 independent reflections
Radiation source: fine-focus sealed tube1552 reflections with I > 2σ(I)
Graphite monochromatorRint = 0.026
ω and φ scansθmax = 28.4°, θmin = 2.9°
Absorption correction: multi-scan (SADABS; Bruker, 2008)h = −13→13
Tmin = 0.873, Tmax = 0.912k = −13→12
6736 measured reflectionsl = −19→14
Refinement on F2Primary atom site location: structure-invariant direct methods
Least-squares matrix: fullSecondary atom site location: difference Fourier map
R[F2 > 2σ(F2)] = 0.036Hydrogen site location: inferred from neighbouring sites
wR(F2) = 0.113H-atom parameters constrained
S = 1.00w = 1/[σ2(Fo2) + (0.0685P)2 + 0.5533P] where P = (Fo2 + 2Fc2)/3
1781 reflections(Δ/σ)max < 0.001
101 parametersΔρmax = 0.25 e Å3
0 restraintsΔρmin = −0.31 e Å3
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes.
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger.
xyzUiso*/Ueq
C10.10770 (15)0.37514 (13)−0.02670 (10)0.0461 (3)
C2−0.07466 (18)0.3213 (2)−0.15100 (11)0.0644 (4)
H2−0.12030.3246−0.21590.077*
C3−0.13428 (17)0.25363 (19)−0.09216 (11)0.0618 (4)
H3−0.21960.2121−0.11780.074*
C40.04654 (14)0.30517 (13)0.03426 (9)0.0417 (3)
C50.05477 (14)0.23121 (15)0.18814 (9)0.0454 (3)
C60.00000.3013 (2)0.25000.0436 (4)
H60.00000.39230.25000.052*
C70.05777 (19)0.09686 (17)0.18801 (10)0.0597 (4)
H70.09790.05160.14700.072*
C80.00000.0305 (2)0.25000.0694 (7)
H80.0000−0.06050.25000.083*
N10.04795 (16)0.38337 (13)−0.11809 (9)0.0580 (3)
N2−0.07257 (13)0.24545 (13)0.00221 (8)0.0515 (3)
O10.11655 (11)0.30189 (12)0.12853 (7)0.0537 (3)
Cl10.26460 (5)0.45456 (4)0.01959 (4)0.06883 (19)
U11U22U33U12U13U23
C10.0581 (7)0.0383 (6)0.0511 (8)0.0030 (5)0.0308 (6)−0.0006 (5)
C20.0681 (10)0.0875 (12)0.0390 (7)0.0107 (9)0.0175 (7)0.0107 (7)
C30.0527 (8)0.0885 (12)0.0432 (8)−0.0002 (8)0.0121 (6)0.0067 (7)
C40.0491 (6)0.0447 (7)0.0363 (6)0.0042 (5)0.0201 (5)0.0004 (5)
C50.0493 (7)0.0565 (8)0.0298 (6)−0.0035 (5)0.0104 (5)0.0000 (5)
C60.0461 (9)0.0492 (10)0.0340 (8)0.0000.0085 (7)0.000
C70.0861 (11)0.0587 (9)0.0385 (7)0.0055 (8)0.0240 (7)−0.0053 (6)
C80.119 (2)0.0472 (12)0.0468 (12)0.0000.0308 (13)0.000
N10.0756 (8)0.0596 (8)0.0484 (7)0.0084 (6)0.0332 (6)0.0117 (6)
N20.0489 (6)0.0689 (8)0.0387 (6)−0.0036 (5)0.0157 (5)0.0063 (5)
O10.0553 (6)0.0703 (7)0.0374 (5)−0.0130 (5)0.0162 (4)−0.0022 (4)
Cl10.0778 (3)0.0608 (3)0.0815 (4)−0.02286 (19)0.0447 (2)−0.01437 (19)
C1—N11.303 (2)C5—C71.373 (2)
C1—C41.4064 (18)C5—C61.3789 (17)
C1—Cl11.7229 (15)C5—O11.3991 (17)
C2—N11.340 (2)C6—C5i1.3789 (17)
C2—C31.362 (2)C6—H60.9300
C2—H20.9300C7—C81.379 (2)
C3—N21.345 (2)C7—H70.9300
C3—H30.9300C8—C7i1.379 (2)
C4—N21.2996 (18)C8—H80.9300
C4—O11.3584 (16)
N1—C1—C4121.76 (14)C6—C5—O1117.57 (14)
N1—C1—Cl1118.42 (11)C5—C6—C5i117.45 (19)
C4—C1—Cl1119.81 (11)C5—C6—H6121.3
N1—C2—C3121.90 (14)C5i—C6—H6121.3
N1—C2—H2119.0C5—C7—C8118.51 (15)
C3—C2—H2119.0C5—C7—H7120.7
N2—C3—C2121.51 (15)C8—C7—H7120.7
N2—C3—H3119.2C7i—C8—C7121.1 (2)
C2—C3—H3119.2C7i—C8—H8119.4
N2—C4—O1120.78 (11)C7—C8—H8119.4
N2—C4—C1121.62 (12)C1—N1—C2116.50 (13)
O1—C4—C1117.60 (12)C4—N2—C3116.71 (13)
C7—C5—C6122.18 (14)C4—O1—C5116.90 (10)
C7—C5—O1120.12 (13)
N1—C2—C3—N2−0.1 (3)C4—C1—N1—C2−0.2 (2)
N1—C1—C4—N20.0 (2)Cl1—C1—N1—C2−179.30 (12)
Cl1—C1—C4—N2179.08 (11)C3—C2—N1—C10.3 (3)
N1—C1—C4—O1179.94 (13)O1—C4—N2—C3−179.81 (14)
Cl1—C1—C4—O1−0.95 (17)C1—C4—N2—C30.2 (2)
C7—C5—C6—C5i−1.04 (11)C2—C3—N2—C4−0.1 (3)
O1—C5—C6—C5i−176.94 (13)N2—C4—O1—C50.4 (2)
C6—C5—C7—C82.0 (2)C1—C4—O1—C5−179.61 (12)
O1—C5—C7—C8177.84 (11)C7—C5—O1—C475.09 (18)
C5—C7—C8—C7i−0.99 (11)C6—C5—O1—C4−108.92 (13)
  7 in total

1.  Synthesis and c-Src inhibitory activity of imidazo[1,5-a]pyrazine derivatives as an agent for treatment of acute ischemic stroke.

Authors:  Harunobu Mukaiyama; Toshihiro Nishimura; Satoko Kobayashi; Tomonaga Ozawa; Noboru Kamada; Yoshimitsu Komatsu; Shinji Kikuchi; Hideki Oonota; Hiroshi Kusama
Journal:  Bioorg Med Chem       Date:  2006-10-24       Impact factor: 3.641

2.  A short history of SHELX.

Authors:  George M Sheldrick
Journal:  Acta Crystallogr A       Date:  2007-12-21       Impact factor: 2.290

3.  Novel 5,7-disubstituted 6-amino-5H-pyrrolo[3,2-b]pyrazine-2,3-dicarbonitriles, the promising protein kinase inhibitors with antiproliferative activity.

Authors:  G G Dubinina; M O Platonov; S M Golovach; P O Borysko; A O Tolmachov; Y M Volovenko
Journal:  Eur J Med Chem       Date:  2006-05-03       Impact factor: 6.514

4.  Imidazo-pyrazine derivatives as potent CXCR3 antagonists.

Authors:  Xiaohui Du; Darin J Gustin; Xiaoqi Chen; Jason Duquette; Lawrence R McGee; Zhulun Wang; Karen Ebsworth; Kirk Henne; Bryan Lemon; Ji Ma; Shichang Miao; Emmanuel Sabalan; Timothy J Sullivan; George Tonn; Tassie L Collins; Julio C Medina
Journal:  Bioorg Med Chem Lett       Date:  2009-07-09       Impact factor: 2.823

5.  Discovery of pyrazine carboxamide CB1 antagonists: the introduction of a hydroxyl group improves the pharmaceutical properties and in vivo efficacy of the series.

Authors:  Bruce A Ellsworth; Ying Wang; Yeheng Zhu; Annapurna Pendri; Samuel W Gerritz; Chongqing Sun; Kenneth E Carlson; Liya Kang; Rose A Baska; Yifan Yang; Qi Huang; Neil T Burford; Mary Jane Cullen; Susan Johnghar; Kamelia Behnia; Mary Ann Pelleymounter; William N Washburn; William R Ewing
Journal:  Bioorg Med Chem Lett       Date:  2007-04-29       Impact factor: 2.823

6.  2-(3-Meth-oxy-phen-oxy)pyrimidine.

Authors:  Shah Bakhtiar Nasir; Zanariah Abdullah; Zainal A Fairuz; Seik Weng Ng; Edward R T Tiekink
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2010-07-31

7.  Structure validation in chemical crystallography.

Authors:  Anthony L Spek
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2009-01-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.